Use of the Onco type DX™ 21-Gene Assay to Guide Adjuvant Decision Making in Early-Stage Breast Cancer

Author： Conlin Alison K.   Seidman Andrew D.  

Publisher： Adis International

ISSN： 1177-1062

Source： Molecular Diagnosis & Therapy, Vol.11, Iss.6, 2007-01, pp. : 355-360

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A study of the impact of the 21‐gene breast cancer assay on the use of adjuvant chemotherapy in women with breast cancer in a Mexican public hospital

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 111, Iss. 2, 2015-02 ,pp. : 203-207

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adjuvant systemic therapy for older adults with early-stage breast cancer

By Pal Sumanta Kumar   Mortimer Joanne  

Women's Health, Vol. 5, Iss. 3, 2009-05 ,pp. : 251-262

Future Medicine

Access to resources Recommend Favorite

The evolving role of adjuvant radiotherapy for elderly women with early‐stage breast cancer

By  

CANCER, Vol. 121, Iss. 14, 2015-07 ,pp. : 2331-2340

John Wiley & Sons Inc

Access to resources Recommend Favorite

The 21-Gene Recurrence Score Assay (Oncotype DX™) in Estrogen Receptor-Positive Male Breast Cancer: Experience in an Israeli Cohort

By  

Oncology, Vol. 87, Iss. 1, 2014-06 ,pp. : 1-6

Karger

Access to resources Recommend Favorite

Treatment decision making in early‐stage papillary thyroid cancer

By  

PSYCHO-ONCOLOGY (ELECTRONIC), Vol. 27, Iss. 1, 2018-01 ,pp. : 61-68

John Wiley & Sons Inc

Access to resources Recommend Favorite